THE LINK BETWEEN VITAMIN В12 DEFICIENCY, RISK OF CARDIOVASCULAR DISEASES AND AGING PROCESS
https://doi.org/10.20996/1819-6446-2017-13-1-100-106
Abstract
Disorder of formation of vitamin B12, which has a wide range of biological properties and is involved in the regulation of many important physiological functions, is the basis of a number of serious diseases. Usually internists consider that vitamin В12 deficiency is associated with disturbances of hematopoiesis or central nervous system. However cobalamin deficiency also affects the state of the cardiovascular system. Its connections to the increased incidence of myocardial infarction, stroke, and congestive heart failure were found, as well as the elevated risk of restenosis after coronary artery bypass surgery. Besides, there are data that demonstrate an association between vitamin В12 and telomere length (a marker of aging). This review presents the main reasons of cobalamin deficiency in the elderly, as well as an analysis of clinical studies that show the link between vitamin В12 deficiency and the risk of cardio-vascular diseases and aging process.
About the Authors
O. M. Drapkina
State Research Center for Preventive Medicine
Russian Federation
Russian Federation
Oxana M. Drapkina – MD, PhD, Professor, Deputy Director for Research and Clinical Work, Head of Department of Fundamental and Applied Aspects of Obesity.
Petroverigsky per. 10, Moscow, 101990
R. N. Shepel
State Research Center for Preventive Medicine
Russian Federation
Russian Federation
Ruslan N. Shepel – MD, Junior Researcher, Department of Fundamental and Applied Aspects of Obesity.
Petroverigsky per. 10, Moscow, 101990
References
1. Hodgkin D.C., Kamper J., Mackay M., et al. Structure of vitamin B12. Nature. 1956;178:64-6.
2. Watanabe F., Yabuta Y., Bito T., Teng F. Vitamin B12-Containing Plant Food Sources for Vegetarians. Nutrients. 2014;6(5):1861-73.
3. The norms of physiological requirements in energy and nutrients for different groups of the Russian population. Methodical recommendations MR 2.3.1.2432-08. Available at: http://rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=4583. Checked by 09/25/2016. (In Russ.) [Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации. Методические рекомендации МР 2.3.1.2432-08. Доступно на: http://rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=4583. Проверено 25.09.2016].
4. Finch S., Doyle W., Lowe C., et al. National Diet and Nutrition Survey: people aged 65 years and over. Volume 1: Report of the diet and nutrition survey. London: TSO; 1998.
5. Carmel R. Cobalamin, the stomach, and aging. Am J Clin Nutr. 1997;66:750-9.
6. Andres E., Affenberger S., Vinzio S., et al. Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment. Am J Med. 2005;118:1154-9.
7. van Asselt D.Z., de Groot L.C., van Staveren W.A., et al. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr. 1998;68:328-34.
8. Fried M., Siegrist H., Frei R., et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut.1994;35:23-6.
9. Carmel R., Perez-Oerez G., Blaser M. Helicobacter pylori infection and food-cobalamin malabsorption. Dig Dis Sci. 1994;39:309-14.
10. Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency. JAMA. 2013;310(22):2435-42.
11. de Jager J., Kooy A., Lehert P., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B12 deficiency: randomised placebo controlled trial. BMJ 2010;340: c2181.
12. Katikova O., Shikh E. Especially vitamin status in patients with liver disease of various etiologies. Possibilities of vitamin therapy. Rossiyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii. 2009; 19(3):21-31. (In Russ.) [Катикова О.Ю., Ших Е.В. Особенности витаминного статуса у больных с заболеваниями печени различной этиологии. Возможности витаминотерапии. Российский Журнал Гастроэнтерологии, Гепатологии, Колопроктологии. 2009; 19(3):21-31].
13. Hughes С.F., Ward M., Hoey L., McNulty H. Vitamin В12 and ageing: current issues and interaction with folate. Annals of Clinical Biochemistry. 2012;50(4):315-29.
14. Perekatova T., Ostroumova M. Once again on the deficiency of vitamin B12. Klinicheskaya Onkogematologiya. 2009;2(2):185-95. (In Russ.) [Перекатова Т.Н., Остроумова М.Н. Еще раз о дефиците витамина В12 . Клиническая Онкогематология. 2009;2(2):185-95].
15. Ciaccio M., Bivona G., and Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Ther Clin Risk Manag. 2008;4(1):219-24.
16. Kostyuchenko G., Barkagan Z. Diagnosis and correction methods of hyperhomocysteinemia in cardiology practice: A guide for doctors. Moscow: GNC RAMN; 2003. (In Russ.) [Костюченко Г.И, Баркаган З.С. Диагностика и методы коррекции гипергомоцистеинемии в кардиологической практике: Пособие для врачей. М.: ГНЦ РАМН; 2003].
17. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc. 2002;288:2015-22.
18. Wald D.S., Law M., Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-8.
19. Noichri Y., Chalghoum A., Chkioua L., et al. Low erythrocyte catalase enzyme activity is correlated with high serum total homocysteine levels in tunisian patients with acute myocardial infarction. Diagn Pathol. 2013; 8: 68.
20. Vasan R.S., Beiser A., D’Agostino R.B., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:1251-7.
21. Kojoglanian S.A., Jorgensen M.B., Wolde-Tsadik G., et al. Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH). Am Heart J. 2003;146(6):1077-81.
22. Faria-Neto J.R., Chagas A.C., Bydlowski S.P., et al. Hyperhomocystinemia in patients with coronary artery disease. Braz J Med Biol Res. 2006;39(4):455-63.
23. Kazemi M.B., Eshraghian K., Omrani G.R., et al. Homocysteine level and coronary artery disease. Angiology. 2006;57(1):9-14.
24. O’Leary F., Samman S. Vitamin B12 in Health and Disease. Nutrients. 2010;2(3):299-316.
25. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-88.
26. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567-77.
27. Spence J.D., Bang H., Chambless L.E., Stampfer M.J. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 2005;36(11):2404-9.
28. Bleie O., Strand E., Ueland P.M., et al. Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12. Coron Artery Dis. 2011;22(4):270-8.
29. Drapkina O., Shepel R. Telomeres and telomerase complex. The main clinical manifestation of genetic malfunctioning. Kardiovaskulyarnaya Terapiya i Profilaktika. 2015;14(1):70-7. (In Russ.) [Драпкина О.М., Шепель Р.Н. Теломеры и теломеразный комплекс. Основные клинические проявления генетического сбоя. Кардиоваскулярная Терапия и Профилактика. 2015;14(1):70-7].
30. Blackburn E.H. Switching and signaling at the telomere. Cell. 2001;106(6):661-73.
31. Rose A., Patel S., Meier I. The plant nuclear envelope. Planta. 2004;218:327-36.
32. Pennaneach V., Putnam C.D., Kolodner R.D. Chromosome healing by de novo telomere addition in Saccharomyces cerevisiae. Mol Microbiol. 2006;59:1357-68.
33. Pedram M., Sprung C.N., Gao Q., et al. Telomere position effect and silencing of transgenes near telomeres in the mouse. Mol Cell Biol. 2006;26(5):1865-78.
34. Olovnik A.I. A theory of marginotomy: the incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41:181-90.
35. von Zglinicki T., Martin-Ruiz C.M. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med.2005;5:197-203.
36. Drapkina O., Shepel R. The modern conception of the proper role of telomeres and telomerase in pathogenesis of hypertension. Arterial'naya Gipertenziya. 2013;19(4):290-8. (In Russ.) [Драпкина О.М., Шепель Р.Н. Современные представления о роли теломер и теломеразы в патогенезе гипертонической болезни. Артериальная Гипертензия. 2013;19(4):290-8].
37. Drapkina O., Shepel R. Telomeres and chronic heart failure. Kardiologiia. 2014;54(4):60-7. (In Russ.) [Драпкина О.М., Шепель Р.Н. Теломеры и хроническая сердечная недостаточность. Кардиология. 2014;54(4):60-7].
38. Ogami M., Ikura Y., Ohsawa M., et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol. 2004;24(3):546-50.
39. Samani N.J., Boultby R., Butler R., et al. Telomere shortening in atherosclerosis. Lancet. 2001;358(9280):472-3.
40. Olivieri F., Mazzanti I., Abbatecola A.M., et al. Telomere/Telomerase system: a new target of statins pleiotropic effect? Curr Vasc Pharmacol. 2012;10(2):216-24.
41. Drapkina O.M., Shepel R.N. Pleotropic effects of vitamin D. Rational Pharmacotherapy in Cardiology
42. ;12(2):227-33 (In Russ.). [Драпкина О.М., Шепель Р.Н. Плейотропные эффекты витамина D. Рациональная Фармакотерапия в Кардиологии. 2016;12(2):227-33].
43. Drapkina O.M., Shepel R.N. Telomere light and atherosclerosis. Rossiyskiy Kardiologicheskiy Zhurnal 2016;(9):84-9 (In Russ.). [Драпкина О.М., Шепель Р.Н. Длина теломер и атеросклероз. Российский Кардиологический Журнал. 2016;9(137):84-9].
44. Lee Y.J., Wang M.Y., Lin M.C., Lin P.T. Associations between Vitamin B12 Status and Oxidative Stress and Inflammation in Diabetic Vegetarians and Omnivores. Nutrients 2016;8(3):118.
45. Weinberg J.B., Chen Y., Jiang N., et al. Inhibition of nitric oxide synthase by cobalamins and cobinamides. Free Radic Biol Med. 2009;46(12):1626-32.
46. Xu Q., Parks C.G., DeRoo L.A., et al. Multivitamin use and telomere length in women. Am J Clin Nutr. 2009;89(6):1857-63.
Review
For citations:
Drapkina O.M., Shepel R.N. THE LINK BETWEEN VITAMIN В12 DEFICIENCY, RISK OF CARDIOVASCULAR DISEASES AND AGING PROCESS. Rational Pharmacotherapy in Cardiology. 2017;13(1):100-106. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-1-100-106
Views:
3654
.jpg)
Email this article 